On June 11th, Alexion and Complement Pharmaceuticals announced that they have reached a cooperation agreement to jointly develop the pre-clinical phase of the complement C6 inhibitor CP010 for the treatment of neurodegenerative diseases.
Complement is a group of thermolabile proteins that exist on the surface of serum, tissue fluid and cell membrane. After activation, they have enzymatic activity and participate in the specific and non-specific immune response of the human body. Therefore, complement is called the complement system. The complement system is composed of three groups of globular macromolecules. The first component is composed of nine complement components named C1-C9, in which C1 is composed of three subunits and is named C1q, C1r, and C1s.
CP010 is a human C6 monoclonal antibody that binds to C6 of the circulatory system to prevent the formation of a membrane attack complex (MAC) in the peripheral and central nervous system. MAC is a protein introduced after complement activation to introduce intracellular damage and is a common terminal pathway of the three complement pathways in the human body. The C6 inhibitory activity of CP010 has been demonstrated in pre-clinical in vivo and in vitro models, with the potential to be developed as drugs for the treatment of various CNS disorders.
According to the agreement, Alexion will work with Complement Pharmaceuticals to complete the preclinical and phase I development of the CP010 project and jointly undertake the CP010 production work. During Phase Ib development, Alexion will pay Complement Pharmaceuticals up to 14 million euros in miles. Alexion also has the right to acquire Complement Corporation as a whole during the cooperation.
Alexion is a pioneer in the study of complement biology and developed and marketed the world’s first complement inhibitor, Soliris. The target of Soliris is C5, which is an important participant in a variety of uncontrolled complement activation-induced diseases. Soliris’ current indications include paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis. Sales in 2017 reached US$3.144 billion.
Alexion executive vice president John Orloff said: Alexion has more than 20 years of research and development experience in the field of complementarity. This cooperation gives us the opportunity to develop new drugs for C6 to treat more diseases. ”
Frank Baas, chief scientist at Complement Pharmaceuticals, said: “Our understanding of the biological effects of the complement system is deepening, and complement activation has been observed in many neurodegenerative diseases. We firmly believe that C6 inhibitors have the potential to treat multiple neurodegenerative diseases. We look forward to working with Alexion, the global leader in the development of complementary drugs, to make this possibility a reality.”